Oral anti-cancer pill plus paclitaxel after immunotherapy failure
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to sign consent and follow the study plan.
- Your cancer is head and neck squamous cell cancer that cannot be fully removed by surgery and has either returned or spread.
- Your cancer has gotten worse after immune checkpoint therapy (like pembrolizumab or nivolumab).
- You must have at least one measurable cancer spot on scans and a good enough energy level (ECOG 0–2).
- Your blood counts and organ tests (bone marrow, kidneys, liver) must be within allowed limits.
- You must not have had certain prior treatments or conditions (like prior taxane chemotherapy for advanced disease, uncontrolled brain metastases, or specific heart rhythm risks).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new light-activated treatment (ASP-1929) combined with an immunotherapy drug (pembrolizumab) as a first treatment for head and neck cancer that has come back in the same area but has not spread to other parts of the body. It aims to see if this combination works better than standard treatment alone.
This trial is testing whether giving a combination of chemotherapy drugs directly into the tumor along with an immunotherapy drug called nivolumab given through an IV can help when head or neck cancer has come back in the same area. The goal is to control the local tumor when other standard treatments haven't worked.
This trial tests a sequence of two drugs, toripalimab (an immunotherapy that helps your immune system fight cancer) and paclitaxel (a chemotherapy drug), for people with head and neck cancer that has spread or cannot be cured. It is designed for patients who have a lower level of physical function (ECOG score of 2) and aims to see if this treatment can help them.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This trial tests if adding immunotherapy after standard chemoradiation helps prevent cancer from returning in people with high-risk head and neck cancer. It is for those who have completed surgery and have certain high-risk features.
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.